News

Latest news

Hide mandatory notifications of trade

Notice of Extraordinary General Meeting 14 December 2016

(Oslo, Norway, 23 November 2016) An Extraordinary General Meeting of Bionor Pharma ASA will be held on Wednesday 14 December 2016 at 16:30 hours CET (the “EGM”) at KS Agenda Møtesenter, Haakon VIIs gate 9, Oslo, Norway.

BIONOR PHARMA ASA

STOCK EXCHANGE ANNOUNCEMENT

Notice of Extraordinary General Meeting 14 December 2016

On 21 November 2016 Bionor Pharma announced (the “Announcement”) that the company has entered into an agreement to acquire the entire share capital of Solon Eiendom AS (the “Acquisition”). In connection the Company will do a Private Placement and a Subsequent Offering as further described in the Announcement. The Acquisition, the Private Placement and the Subsequent Offering are subject to shareholder approval and the Company accordingly call the EGM for the purpose of obtaining such shareholder approval. The largest shareholders of the Company, including Ferncliff Listed DAI, Lars H. Høie, Cipriano AS and Alden AS, have signed a lock-up undertaking until the EGM and have undertaken to vote in favour of such resolutions at the EGM.

Link to the notice of the EGM in pdf is attached hereto and includes detailed registration and proxy instructions.

All relevant documents and link to online registration of attendance and advance voting can be found on www.bionorpharma.com.

Link to online registration of attendance and advance voting please click here.

Please note that to attend the EGM, attendants must be registered shareholders five working days prior to the meeting, i.e. 7 December 2016.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
 
Further information
Einar J. Greve Chairman of the Board, Bionor Pharma ASA E-mail: ejg@cipriano.no Cell Phone: +47 900 27 766
Unni Hjelmaas Acting Chief Executive Officer, Bionor Pharma ASA E-mail: uh@bionorpharma.com Cell Phone: +47 915 19 651
Cecilie Grue, Director Legal Affairs, Bionor Pharma ASA, E-mail: cg@bionorpharma.com, Cell Phone: +47 991 62 486

Link to notice in pdf

Link to Expert statement on the non-cash share contribution in pdf

Link to Recommendations of the Nomination Committee in pdf

Link to announcement in pdf